Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:
stock market futures: Brown Forman Corporation(BF.B)
- [By Chris Lange]
The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday Brown-Forman Corp. (NYSE: BF.B) which rose nearly 7% to $66.01. The stocks 52-week range is $64.29 to $67.98. Volume was over just over 1 million compared to its average volume of 0.7 million.
stock market futures: Sirius XM Radio Inc.(SIRI)
- [By Rick Munarriz]
There are a lot of people betting against Sirius XM Radio (NASDAQ:SIRI)these days, even as the stock is hitting 10-year highs. There were 280.1 million shares of Sirius XM sold short at the end of 2016, just below the late-November peak of 285.1 million shares but nearly double the short interest that we were seeing a year ago.
- [By Ashley Moore]
But before we get to the stock pick, here’s a list of the 10 top-performing Warren Buffett stocks so far this year…
Company YTD Gains
Moody’s Corp. (NYSE: MCO) 34.25%
Apple Inc. (Nasdaq: AAPL) 30.24%
Verisign Inc. (Nasdaq: VRSN) 29.88%
Restaurant Brands Inc. (NYSE: QSR) 29.16%
WABCO Holdings Inc. (NYSE: WBC) 28.97%
Visa Inc. (NYSE: V) 26.20%
Liberty Sirius XM Group Class C (Nasdaq: LSXMK) 24.54%
MasterCard Inc. (NYSE: MA) 24.35%
Liberty Sirius XM Group Class A (Nasdaq: LSXMA) 22.89%
Sirius XM Holdings Inc. (Nasdaq: SIRI) 22.81%
Again, we don’t recommend all of the stocks above for retail investors. After all, Warren Buffett is one of the most wealthy and legendary investors in history. He has a completely different set of goals from us.
- [By Peter Graham]
A long term performance chart shows Pandora Mediapeaking in 2014 before heading back to where it started while other streaming media stocks such as large cap satellite radio stockSirius XM Radio Inc (NASDAQ: SIRI) has performed better and InternetTV stock Netflix, Inc (NASDAQ: NFLX) has been a homerun:
- [By Jon C. Ogg]
The long saga regarding Pandora Media Inc. (NYSE: P) has finally come to a head. Well, maybe. Rather than KKR & Co. L.P. (NYSE: KKR) investing $150 million, Sirius XM Holdings Inc. (NASDAQ: SIRI) will be investing up to $480 million in the streaming music rival. With its ticketing unit sale taking place as well, it might seem that Pandora is getting a great deal and helping to bolster its books.
stock market futures: Endologix, Inc.(ELGX)
- [By Paul Ausick]
Endologix Inc. (NASDAQ: ELGX) dropped about 9.3% on Wednesday to post a new 52-week low of $4.78 against a 52-week high of $14.50 and a Tuesday close of $5.27. Volume of about 6 million was more than 3 times the daily average of around 1.7 million. The company on Tuesday announced a temporary shipping hold on its best-selling heart device, saying there was a manufacturing issue.
- [By Lisa Levin]
Endologix, Inc. (NASDAQ: ELGX) shares dropped 23 percent to $7.59 as the company issued an update on Nellix PMA process. Endologix disclosed that the FDA has requested the company to provide a two-year patient follow-up data from the EVAS-FORWARD IDE study of Nellix System.
stock market futures: 2U, Inc.(TWOU)
- [By David Kretzmann]
Since its IPO in March 2014, 2U (NASDAQ:TWOU) stock is up over 160% as the company forges partnerships with famous schools, including Georgetown, Yale, Berkeley, and New York University.
stock market futures: AMAG Pharmaceuticals, Inc.(AMAG)
- [By Lisa Levin]
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) were down around 36 percent to $22.95. Before the open, the issue company issued FY 2017 sales that surrounded current estimates. Also, the company announced an exclusive licensing agreement with Palatin Technologies, Inc. (NYSE: PTN) for North American rights to Rekyndatm. Raymond James downgraded AMAG Pharmaceuticals from Market Perform to Underperform.
- [By WWW.MONEYSHOW.COM]
Makena is the flagship drug from AMAG Pharmaceuticals (AMAG); the drug helps reduce the risk of preterm birth.
The company’s blood registry preserves newborn stem cells used to treat blood and immune disorders.